Guest guest Posted February 14, 2003 Report Share Posted February 14, 2003 DISCUSSION This analysis takes advantage of the large number of sites and patients reporting to the ESCF. It presents an opportunity to study outcomes and practices in a comprehensive way. The approach was to compare CF care sites based on an important index of lung health (ie, the percentage of predicted FE[V.sub.1] values). Large differences in lung health across sites were demonstrated. The sites reporting the highest values for median FE[V.sub.1]monitored patients, obtained measurements of lung function, and obtained cultures for respiratory pathogens more frequently. The differences in monitoring were most striking for spirometry testing and respiratory cultures, and were less marked for visit frequency. Also at these sites, more patients of all ages were prescribed inhaled cromolyn or nedocromil and oral corticosteroids for all degrees of disease severity. Adult patients at these sites were prescribed bronchodilator agents, dornase alfa, and inhaled corticosteroids more frequently than their lower quartile counterparts. At upper quartile sites, IV antibiotics were used more frequently and for longer duration. It is possible that this increased use of antibiotics may have resulted in the increase in prevalence of bacterial strains, including resistant strains that were noted at the upper quartile sites. However, we have reported previously an increase in the detection of organisms and resistance at sites that monitor more frequently. (19) Data were presented only for the upper and lower quartile sites, but the results are further supported by the fact that for the two middle quartiles the results generally lie between those for the upper and lower quartiles. There are exceptions to this generalization, but these are primarily in the severely ill patients where the numbers are relatively small. It also should be noted that the generalizability of these observations may be limited by the exclusion of sites with < 50 patients. Also, the decision by a number of Canadian sites not to participate in the study may have affected the interpretation of the results. Possible explanations for the substantial differences in lung function results between the upper and lower quartile sites include differences in the patterns of practice, but they might also include genetic or other differences in the local patient populations, differences in local conditions including climate, the distance that patients live from the site, and socioeconomic status. Data from the CF Foundation Registry indicate that in 1996 only 226 of the 19,570 patients (1.4%) reported a lack of insurance coverage, so at least this aspect of socioeconomic status is not likely to be an important factor. (20) Upper quartile sites were somewhat more likely to be located in the northeastern region of the United States, and, in the pediatric age groups only, there was a tendency toward larger sites in the upper quartile compared to the lower quartile. Although the results of this study suggest that the upper quartile sites were more likely to perform special assessments and prescribe some therapies, another possible explanation that always exists in observational studies is more thorough reporting of these events at upper quartile sites. To guard against this possibility, each site received patient-specific data reports and was requested to verify the accuracy of their data. The use of nonsteroidal anti-inflammatory drugs was not considered because, at the time of this study, the ESCF did not distinguish high-dose ibuprofen therapy (9) from the analgesic use of nonsteroidal anti-inflammatory medications. Oral nonquinolone antibiotics were extensively used for treatment of patients across all age and severity groups. Those antibiotics were used significantly less often in adolescent and adult patients at the lower quartile centers than in those patients at the upper quartile centers. These data are consistent with those from a study undertaken in the United Kingdom (21) indicating improved outcomes for young CF patients who received long-term antistaphylococcal therapy. Regarding the use of antibiotics to treat pulmonary exacerbations, the most striking differences between upper and lower quartile sites occurred in patients < 18 years of age, particularly in the adolescent age group. Adolescents from upper quartile sites received more treatment with IV and inhaled antibiotics, and less treatment with oral quinolones. For IV and inhaled antibiotics, the differences were greater for patients with milder lung disease, suggesting that these patients were treated more aggressively. The duration of treatment with IV antibiotics was also greater in upper quartile sites in adolescents, as well as in adults. More intensive use of IV and inhaled antibiotics at upper quartile sites might account for the better lung function observed in patients at these sites. The identification of a pulmonary exacerbation warranting antibiotic therapy, particularly IV therapy, may be related to the frequency of obtaining spirometry, since a fall in FE[V.sub.1] values commonly results in treatment for a pulmonary exacerbation. Whatever leads to the decision to treat, it appears that the upper quartile sites are treating patients more often, particularly those considered to have mild lung disease. One possible conclusion from these data is that the use of antibiotics contributes to the improved outcomes seen in patients at upper quartile sites. Support for intensive antibiotic therapy comes from data reported in a Danish study, (17) which have shown that a program of quarterly hospital admissions for IV antipseudomonal therapy is associated with improved survival. Further support for intensive antibiotic therapy also comes from studies of inhaled, high-dose tobramycin. (10) However, other factors in Denmark, such as attention to nutritional support and access to state-supported health care facilities, also may play a role in improved outcomes. These data suggest a greater prevalence of multiply resistant P aeruginosa, B cepacia, and S maltophilia at upper quartile sites. This could represent an important and disturbing association between increased antibiotic use and the emergence of resistant strains. It is possible that this results from an ascertainment bias due to the higher frequency of cultures in the upper quartile sites. We have shown previously (20) that increased frequency of cultures and better culture techniques result in the increased identification of resistant organisms. This observation highlights the need for continued research into improved antimicrobial agents and a better understanding of the mechanisms of colonization and infection of the lung and the development of antibiotic resistance in CF. Both inhaled cromolyn or nedocromil and oral corticosteroids were administered more often at upper quartile sites. The association between poor outcomes in CF patients and a vigorous inflammatory response was first noted by Wheeler et al (22) and led to a large multicenter trial (23) of oral corticosteroid use in CF patients. Although this study showed a clear benefit in terms of the maintenance of pulmonary function, a 1996 review (4) stated that the adverse effects on linear growth and glucose metabolism should limit the long-term use of oral corticosteroids. This analysis demonstrates the widespread use of both oral and inhaled corticosteroids but does not distinguish between long-term and sporadic use. A surprising result of this analysis is the finding of an increased administration of inhaled cromolyn or nedocromil at upper quartile sites These agents are known to modulate the inflammatory response but are also reported to block non-CF transmembrane receptor chloride channels. (24,25) Cromolyn-mediated or nedocromil-mediated blocking of chloride channels would appear to be counterproductive. The strength of the observed association warrants investigation into possible mechanisms that might explain this paradox. In summary, this large observational study of CF demonstrates significant and clinically relevant differences across sites in lung health as measured by FE[V.sub.1] . The striking finding of this analysis is the consistency with which the sites in the upper quartile, regardless of age and disease severity, monitor and treat patients more frequently than do lower quartile centers. This association is particularly strong for younger and relatively healthy CF patients. These results suggest, but do not prove, the hypothesis that frequent monitoring and more interventions, including the more frequent use of IV antibiotics for longer duration, potentially result in better outcomes for CF patients. Becki YOUR FAVORITE LilGooberGirl YOUNGLUNG EMAIL SUPPORT LIST www.topica.com/lists/younglung Pediatric Interstitial Lung Disease Society http://groups.yahoo.com/group/InterstitialLung_Kids/ Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.